Figure 4. DARS-AS1 promoted LUAD growth in vivo. (A) LUAD transfected with si-DARS-AS1 had smaller tumors, while (B) the DARS-AS1 ov transfection group had larger tumors. The average tumor volume of LUAD transfected with (C) si-DARS-AS1 (p < 0.05 compared to si-NC) or (D) DARS-AS1 ov (p < 0.05 compared to NC group) was continuously measured over 21 days. After 21 days, the average tumor weight of LUAD transfected with (E) si-DARS-AS1 (p < 0.01) or (F) DARS-AS1 ov (p < 0.01) was scored. (G) The si-DARS-AS1 group had smaller tumors and fewer spreading lesions in the lung than the si-NC group. (H) The DARS-AS1 ov group had larger tumors and more spreading lesions in the lung than the NC group.